Gtreat news and probably what has caused the volume...

Gtreat news and probably what has caused the volume lately.

Regards, TCG


GIACONDA RECEIVES NON-BINDING LOI FOR COMMERCIALISATION OF MYOCONDA™ IN UK
Sydney, Australia. 13 April 2006. Giaconda Limited (ASX: GIA) today announced that it has
received a non-binding letter of intent (LOI) from Forest Laboratories UK Limited regarding the
licensing and commercialisation of its lead product for Crohn’s disease, Myoconda®.
In this LOI Forest Laboratories has expressed its intention to undertake due diligence with the
objective of acquiring the exclusive rights to commercialise Myoconda® in the UK and Ireland. The
license agreement will be executed prior to Giaconda commencing the Phase IIIb clinical trial which is
expected to occur in this calendar year.
“We are very excited about entering this relationship with Forest Laboratories, who we believe to be
an ideal partner for Giaconda in this major territory,” said Patrick McLean, CEO of Giaconda.
“Giaconda is committed to commercialising Myoconda® by choosing the most appropriate partners for
each territory and this letter of intent signals the beginning of our progress in this area,” he added.
Crohn’s disease affects between 30,000 and 60,000 people in the UK with 3,000-6,000 new cases
being diagnosed each year. Research shows that the number of people with Crohn’s disease has
been rising steadily, particularly among young people.*
“The commercialisation of Myoconda® would give us an opportunity to provide alternative treatment to
a patient group that is currently underserved by existing therapies,” commented John Worth, Sales &
Marketing Director of Forest Laboratories UK.
* National Association for Colitis and Crohn's Disease (NACC)
About Giaconda Limited
Giaconda Limited is a biotechnology company involved in developing and licensing innovative and
cost effective medical therapies in the field of gastroenterology. Giaconda’s products are targeted
towards the treatment of serious conditions that are not adequately addressed by any existing therapy.
In this way, Giaconda’s products are intended to satisfy these significant unmet medical needs of the
gastrointestinal market. The Giaconda portfolio consists of five products, all of which are novel
combinations of known compounds. Giaconda has two lead products, Myoconda® for the treatment of
Crohn’s Disease and Heliconda® for the treatment of resistant Helicobacter pylori infection. Both of
these products are ready for Phase III clinical trials, with a Phase IIIa already complete for
Myoconda®.